A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)

A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)

Abstract Background Patients with activating epidermal growth factor receptor (EGFR) mutations are highly responsive to EGFR-tyrosine kinase inhibitors (TKIs). However, it has been reported that approximately 15–30% of patients treated with EGFR-TKIs experience central nervous system (CNS) progressi...

Full description

Bibliographic Details
Main Authors: Kazushige Wakuda, Hiroyuki Yamaguchi, Hirotsugu Kenmotsu, Minoru Fukuda, Masafumi Takeshita, Takayuki Suetsugu, Keisuke Kirita, Noriyuki Ebi, Osamu Hataji, Satoru Miura, Kenji Chibana, Isamu Okamoto, Kenichi Yoshimura, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Kenji Sugio
Format: Article
Language:English
Published: BMC 2020-05-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer
EGFR T790M
CNS metastasis
Brain metastasis
Osimertinib
Online Access:http://link.springer.com/article/10.1186/s12885-020-06874-6

Internet

http://link.springer.com/article/10.1186/s12885-020-06874-6

Similar Items